Information Provided By: 
Fly News Breaks for November 26, 2018
AMRN
Nov 26, 2018 | 11:21 EDT
Cantor Fitzgerald analyst Louise Chen thinks the peak sales potential of Amarin's Vascepa is "underappreciated" following what she viewed as overwhelmingly positive data at AHA. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive the company's shares higher, she argues. The analyst notes that Amarin remains on track to submit a sNDA to expand its labeling for REDUCE-IT in early 2019, with approval expected in late 2019. Chen reiterates an Overweight rating and $35 price target on the shares.
News For AMRN From the Last 2 Days
There are no results for your query AMRN
